According to the innovative mechanism, taking advantage of the policy wind, Professor Ma Jun shares the new thinking of lymphoma treatment in the new era

In recent years, the emergence of a variety of targeted drugs has provided more choices for the treatment of lymphoma patients in China; the popularization of medical insurance policies has also allowed more patients to experience the efficacy of new drugs, so the overall survival of lymphoma patients in China has improved
.

Timely sorting out and summarizing experience will help to further improve the level of lymphoma diagnosis and treatment in China
.

From April 29th to 30th, 2022, the working meeting of the Chinese Society of Clinical Oncology (CSCO) Leukemia Expert Committee & Lymphoma Expert Committee and the 2022 Leukemia and Lymphoma Summit Forum will be held, and the Lymphoma Forum will discuss the progress of lymphoma.
details
.

On this occasion, Yimaitong specially invited Professor Ma Jun, director of the Harbin Institute of Hematology and Oncology, to interpret the significance of the summit forum, review the history of lymphoma immunotherapy, grasp the frontier progress in the field of lymphoma, and look forward to the feasible way of lymphoma treatment in the future
.

Yi Mai Tong: During the special period of the epidemic, it is very commendable that CSCO can hold the 2022 Leukemia and Lymphoma Summit Forum online
.

As the executive chairman of this summit forum, can you talk about the original intention and significance of the forum? Professor Ma Jun's Leukemia and Lymphoma Summit Forum is one of the most important meetings of the CSCO Leukemia Expert Committee and Lymphoma Expert Committee every year.
Comprehensive communication platform
.

The original intention of the forum is to integrate various academic ideas, deepen industry-university-research cooperation, and improve the diagnosis and treatment level of leukemia and lymphoma workers, thereby promoting the prosperity and development of leukemia and lymphoma in China
.

The new era has given us a new direction.
As doctors, we must adhere to the concept of "life above everything else" and strive to achieve the "5-year survival rate of malignant tumor patients increased by 15%" in the "Healthy China 2030" Plan Outline.
Strategic goal of achieving a 5-year survival rate of 46% for lymphoma patients
.

Therefore, to a certain extent, this summit forum is not only an academic seminar, but also a signal calling on relevant domestic practitioners to work hard to achieve the grand goal of "Healthy China"
.

To this end, doctors should promote the standardization, precision, and individualization of diagnosis and treatment in light of domestic clinical conditions.
At the same time, they should actively combine forces from all sectors of society and work closely with pharmaceutical companies and relevant institutions to steadily achieve the established strategic goals under the guidance of relevant policies
.

Yi Mai Tong: "Healthy China 2030" puts forward higher requirements for the survival rate of lymphoma patients.
In order to achieve this goal, we must first have a clear understanding of lymphoma treatment.
The difficult exploration and continuous breakthroughs in the field of lymphoma have been made all the way.
Could you please review this process and talk about the changes in the treatment model in the field of lymphoma? Professor Ma Jun's lymphoma mainly includes Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL).
The incidence of NHL is much higher than that of HL
.

The most common type of NHL is B-cell lymphoma, including follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).
A microcosm of the process
.

In the pre-immunotherapy era, clinical tumor treatment was mainly radiotherapy and chemotherapy
.

In 1997, the immune-targeted drug anti-CD20 monoclonal antibody, rituximab, was approved by the U.
S.
Food and Drug Administration (FDA) for the treatment of relapsed and refractory low-grade malignant or follicular B cell non-Hodgie Golden lymphoma, pioneered the immunotargeted therapy for B-cell lymphoma
.

After numerous clinical trials and real-world research, the treatment mode of the drug combined with chemotherapy has become the standard for the first-line treatment of tumors such as DLBCL and FL, benefiting many patients
.

In the field of DLBCL, rituximab in combination with chemotherapy remains the current gold standard
.

In the field of FL, the launch of octuzumab further promotes the development of FL treatment
.

A large amount of evidence-based medical evidence shows that octuzumab combined with chemotherapy is more effective than rituximab combined with chemotherapy
.

At present, authoritative guidelines at home and abroad have made it clear that otuzumab combined with chemotherapy is the new standard and cornerstone of the first-line treatment of FL
.

Yimaitong: Tumor treatment is a process of continuous development.
Could you please talk about how this process has brought about the clinical treatment of lymphoma in the context of the development of drugs in the field of lymphoma, especially B-cell lymphoma, which was just mentioned.
inspired? Whether Professor Ma Jun's drugs are standardized and accessible is the key to whether the current situation of tumor treatment can be improved
.

Guideline recommendation and medication consensus are the guarantees to promote the standardized application of clinical drugs.
Every year, the CSCO guideline will update the relevant content of disease diagnosis and treatment based on the latest progress of the disease
.

The new version of CSCO in 2022 updated the content of the first-line treatment of FL to use octuzumab combined with chemotherapy as the new standard, which further promoted the standardized treatment in the clinical field of FL
.

Policy support such as medical insurance is the internal driving force for tumor drugs to be truly used by the people
.

In 2021, as many as 18 anti-tumor drugs will enter China's medical insurance, and anti-lymphoma drugs such as octuzumab, bendamustine, and the BTK inhibitor orelabrutinib are all listed.
New drugs that have been on the market soon entered medical insurance, benefiting many patients and becoming a model for the availability of new drugs
.

In addition, the research and development of innovative drugs is the driving force for the continuous innovation of clinical tumor treatment models
.

As can be seen from the changes in the treatment model in the field of B-cell lymphoma, changes in treatment standards often benefit from the birth of new drugs
.

From chemoradiotherapy to rituximab, to the self-innovation of anti-CD20 monoclonal antibody - the launch of otuzumab, the emergence of innovative drugs is an important factor driving the change of the diagnosis and treatment model
.

Recently, the CD79b-targeting antibody-drug conjugate Polatuzumab Vedotin (Pola) and the CD20/CD3-targeting bispecific antibody Glofitamab have also attracted much attention recently for the treatment of DLBCL
.

The results of the global phase III POLARIX study showed that the Pola-R-CHP regimen significantly reduced the relative risk of disease progression, recurrence or death by 27% compared with the R-CHOP regimen (HR 0.
73; 95%CI: 0.
57-0.
95; P<0.
02), which was The patients with newly diagnosed DLBCL have brought new hope; this CSCO guideline recommended the treatment of newly diagnosed DLBCL earlier than the NCCN guideline, and it is the first known important guideline in the world to recommend Pola for newly diagnosed DLBCL
.

Preliminary results from an ongoing Phase I/II dose escalation/expansion study show favorable efficacy and safety of Glofitamab monotherapy in patients with relapsed, refractory, aggressive NHL (aNHL), and in patients with evaluable aNHL (n=175 ), the objective response rate (ORR) was 53.
7%, the complete response rate (CR) was 39.
4%, and 72.
5% of patients who achieved CR were still in CR at the time of analysis
.

Whether these drugs can set off "waves" in the field of lymphoma still needs more clinical trials to temper
.

Yimaitong: Could you please look forward to the future direction of lymphoma treatment in my country based on the current progress in the field of lymphoma and the latest updated CSCO guidelines? Professor Ma Jun's targeted therapy drugs are currently and will be a research hotspot in the field of lymphoma treatment in the future, which is closely related to the standardization, precision and individualization of diagnosis and treatment
.

Therapeutic drugs in the field of lymphoma show the characteristics of "a hundred flowers blooming".
Monoclonal antibodies, small molecule targeted drugs, chimeric antigen receptor T cells (CAR-T), antibody-drug conjugates, and bispecific antibodies have their own merits
.

In addition, exploring different drug use patterns is also a direction that should be paid attention to in the future.
For example, anti-CD20 monoclonal antibody combined with chemotherapy or other targeted drugs may help to solve the unmet clinical needs of lymphoma patients
.

All in all, the innovation of clinical drugs and the update of treatment models are ultimately for the better survival of patients and even clinical cure.
Hospitals and related enterprises should rely on China's policy support to actively explore and practice the clinical application of drugs, optimize the current situation.
There is a treatment model, and we work together to achieve the goal of "Healthy China 2030"
.

Summary By reviewing the evolution of the treatment model in the field of lymphoma and summarizing the experience in the availability of drug regulations, it can be seen that new drug development and policy support are the "two carriages" that drive the continuous development of tumor treatment, and are heading towards higher clinical cure goals.
The process is even more inseparable from the close cooperation of medical institutions, pharmaceutical companies, and the government
.

At present, the overall survival of lymphoma patients in China has improved significantly, but practitioners from all walks of life should not be satisfied with this, but should work together to continue to strive for the well-being of lymphoma patients
.

Expert Profile Professor Ma Jun Chief Physician, Doctoral Supervisor Director of Harbin Institute of Hematology and Oncology Chairman of the Supervisory Board of the Chinese Society of Clinical Oncology (CSCO) Vice Chairman of the Asian Society of Clinical Oncology Chairman of the Leukemia Expert Committee of the Chinese Society of Clinical Oncology National Health Commission Construction and Continuing Education Center Lymphoma Specialist Construction Project Expert Team Leader Honorary Consultant of the Nursing Group of the Lymphoma Expert Committee of the Chinese Society of Clinical Oncology New progress in lymphoma treatment and prospect of possible trends in future treatment
.

Want to hear more celebrities share their insights on lymphoma diagnosis and treatment? Want to explore the mysteries of rare diseases in the blood field? Want to learn more about the latest developments in various new medicines? Pay attention to the 2022 Blood Luo Cube Summit on April 30, 2022 - Inheritance of blood and mission to heal each other, many celebrities gathered together to review the history of fighting lymphoma, discuss the latest progress in the field of lymphoma, and look forward to the future
.

   Editor: Valamor Typesetting: XY, Wenting, Uni, Quinta Execution: Quinta pokes "read the original text", we make progress together